-
Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging
Friday, August 5, 2016 - 2:25pm | 392Read More...Deutsche Bank has downgraded Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to Sell from Hold on valuation. Despite acknowledging the long-term potential of Ligand's "more than 150 shots-on-goal," the brokerage sees downside in shares over the next one year if there is lag in revenue momentum and lack...
-
Stephens Calls Ligand 'Unique,' Sees $150/Share Coming By 2017
Wednesday, April 13, 2016 - 9:33am | 519Read More...Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a unique biotech play that offers long-term staged growth profile, according to a note from Stephens, which initiated coverage of the stock with an Overweight (Volatile) rating. The brokerage has $150 price target on the stock, representing an upside of...
-
Market Wrap For February 3: Bears In Complete and Absolute Control
Monday, February 3, 2014 - 5:45pm | 2594Read More...U.S. stocks continued its losses on an accelerated basis on Monday. Investors are in clear panic mode following a report that U.S manufacturing activity expanded at a slower pace in January. The Dow plunged more than 300 points while the S&P 500 and Nasdaq both fell more than two percent as...
